摘要
目的：观察序贯甘露聚糖肽联合DCF方案治疗晚期胃癌的临床疗效。方法：收集笔者所在医院2008年4月-2012年9月期间住院治疗的胃癌患者110例，随机分为治疗组、对照组、安慰组，分别为50例、30例、30例，三组均采用DCF方案化疗，治疗组患者住院期间使用甘露聚糖肽注射液，出院口服甘露聚糖肽胶囊；对照组患者住院期间使用注射用胸腺肽，出院口服胸腺肽肠溶胶囊；安慰组患者住院期间静脉点滴等体积的注射用生理盐水，出院口服安慰剂。结果：治疗组T淋巴细胞亚群CD4＋、CD8＋、CD4＋/CD8＋显著提高，与对照组比较均具有统计学差异（P〈0.05）。治疗组临床有效率为64.00%，生活质量改善有效率为72.00%，显著优于对照组和安慰组（P〈0.05）。结论：应用序贯甘露聚糖肽联合DCF化疗方案治疗晚期胃癌，能显著增强患者机体细胞免疫功能，提高临床疗效，改善患者生存质量。
Objective：To observe the clinical effect of Mannatide sequential therapy combined with DCF chemotherapy to treat advanced gastric cancer.Methods：110 cases of patients with advanced gastric cancer that were selected in the period of April 2008 to September 2012,were randomly divided into treatment group and control group and the placebo group,50 cases,30 cases,30 cases respectively.On the basis of DCF chemotherapy,the treatment group was treated with Mannatide injection in the hospitalization,and took orally Mannatide capsule after hospital discharge;control group was applied the thymosin injection during hospitalization,and took orally thymosin enteric-coated capsules after hospital discharge;placebo group was applied equal volume of saline in the hospitalization and took orally placebo after hospital discharge.Results：The T lymphocyte subsets CD4＋,CD8＋,CD4＋/CD8＋ of treatment group increased significantly.Compared with control group,the difference was statistically significant （P〈0.05）.The clinical response rate of treatment group was 64.00%,and the effective rate of life improving was 72.00%,which were significantly better than the control group and the placebo group （P〈0.05）.Conclusion：The application of Mannatide sequential therapy combined with DCF chemotherapy to treat advanced gastric cancer can significantly enhance immune function,improve clinical efficacy,and improve patients＇ life quality.
出处
《中国医药导刊》
2014年第2期288-289,292,共3页
Chinese Journal of Medicinal Guide
